Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 188

1.
3.

p53 immunostaining in differential diagnosis of pleural mesothelial proliferations.

Esposito V, Baldi A, De Luca A, Claudio PP, Signoriello G, Bolognese A, Centonze P, Giordano GG, Caputi M, Baldi F, Giordano A.

Anticancer Res. 1997 Jan-Feb;17(1B):733-6.

PMID:
9066611
4.

Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium.

Ramael M, Lemmens G, Eerdekens C, Buysse C, Deblier I, Jacobs W, van Marck E.

J Pathol. 1992 Dec;168(4):371-5.

PMID:
1484318
6.

p53 expression is common in malignant mesothelioma.

Kafiri G, Thomas DM, Shepherd NA, Krausz T, Lane DP, Hall PA.

Histopathology. 1992 Oct;21(4):331-4.

PMID:
1398535
7.

Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies.

Roberts F, Harper CM, Downie I, Burnett RA.

Am J Clin Pathol. 2001 Aug;116(2):253-62.

PMID:
11488073
8.
9.

The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation.

Soosay GN, Griffiths M, Papadaki L, Happerfield L, Bobrow L.

J Pathol. 1991 Apr;163(4):299-305.

PMID:
2033489
10.
12.

Assessment of cell cycle state may facilitate the histopathological diagnosis of malignant mesothelioma.

Sington JD, Morris LS, Nicholson AG, Coleman N.

Histopathology. 2003 May;42(5):498-502.

PMID:
12713628
13.

Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation.

Shi M, Fraire AE, Chu P, Cornejo K, Woda BA, Dresser K, Rock KL, Jiang Z.

Am J Surg Pathol. 2011 Jun;35(6):878-82. doi: 10.1097/PAS.0b013e318218985b.

PMID:
21566519
15.

The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.

Hasteh F, Lin GY, Weidner N, Michael CW.

Cancer Cytopathol. 2010 Apr 25;118(2):90-6. doi: 10.1002/cncy.20071.

16.

Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas.

Chiosea S, Krasinskas A, Cagle PT, Mitchell KA, Zander DS, Dacic S.

Mod Pathol. 2008 Jun;21(6):742-7. doi: 10.1038/modpathol.2008.45. Epub 2008 Mar 7.

17.

[Thoracoscopic anatomy, significance of pathologic findings in thoracoscopic open lung biopsy, and pleural mesothelioma].

Kawai T, Watanabe M, Takagi K.

Nihon Kyobu Shikkan Gakkai Zasshi. 1994 Dec;32 Suppl:142-7. Review. Japanese.

PMID:
7602822
19.

The separation of benign and malignant mesothelial proliferations.

Churg A, Colby TV, Cagle P, Corson J, Gibbs AR, Gilks B, Grimes M, Hammar S, Roggli V, Travis WD.

Am J Surg Pathol. 2000 Sep;24(9):1183-200. Review.

PMID:
10976692

Supplemental Content

Support Center